LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To monitor the response to treatment of invasive breast cancer and to help watch for recurrence of the disease
When you have been or are being treated for invasive breast cancer
A blood sample drawn from a vein in your arm
Cancer antigen 15-3 (CA 15-3) is a protein that is produced by normal breast cells. In many people with cancerous breast tumors, there is an increased production of CA 15-3 and the related cancer antigen 27.29. CA 15-3 does not cause cancer; rather, it is shed by the tumor cells and enters the blood. This test measures CA 15-3 in the blood.
Since CA 15-3 can be measured in the blood, it is useful as a tumor marker to follow the course of the cancer. CA 15-3 is elevated in fewer than 50% of women with early localized, breast cancer or with a small tumor, but is elevated in about 80% of those with breast cancer that has spread (metastatic). Because not all women with invasive breast cancer will have elevated CA 15-3, the test is not useful in all cases.
CA 15-3 is not recommended as a screening test to detect breast cancer in women because it is non-specific. It may also be elevated in healthy people and in individuals with other cancers such as colon, lung, pancreas, ovarian, or prostate malignancies or certain conditions such as cirrhosis, hepatitis, and benign breast disease.
The cancer antigen 15-3 (CA 15-3) test and the related CA 27.29 test are mainly used to monitor response to breast cancer treatment and to help watch for breast cancer recurrence. They are used along with other clinical evaluations and tests, such as estrogen and progesterone receptors, Her2/neu, and gene expression tests for breast cancer, to evaluate a person's breast cancer.
CA 15-3 is sometimes ordered to provide a general sense of how much cancer may be present (the tumor burden). CA 15-3 can only be used as a marker if the cancer is producing elevated amounts of it, so this test is not useful for all people with breast cancer.
The CA 15-3 and CA 27.29 tests are not sensitive or specific enough to use as a screening test for cancer because non-cancerous conditions can cause elevated levels.
CA 15-3 may be ordered along with other tests when advanced breast cancer is first diagnosed to help determine cancer characteristics and treatment options. If CA 15-3 is initially elevated, then it may be ordered periodically to monitor the effectiveness of treatment and to help watch for recurrence. CA 15-3 is usually not ordered when breast cancer is detected early, before it has spread (metastasized), because levels will not be elevated in the majority of early cancers.
In general, the higher the CA 15-3 level, the more advanced the breast cancer and the greater the amount of cancer present (tumor burden). CA 15-3 concentrations tend to increase as the cancer grows. In metastatic breast cancer, the highest levels of CA 15-3 often are seen when the cancer has spread to the bones and/or the liver.
Increasing concentrations of CA 15-3 over time may indicate that a person is not responding to treatment or that the cancer is recurring.
Normal CA 15-3 levels do not ensure that a person does not have localized or metastatic breast cancer. It may be too early in the disease process for elevated levels of CA 15-3 to be detected or the person may be one of the roughly 20% to 25% of individuals with advanced breast cancer whose tumors do not shed CA 15-3.
Mild to moderate elevations of CA 15-3 are seen in a variety of conditions, including cancer of the lung, pancreas, ovary, prostate, and colon as well as cirrhosis, hepatitis, and benign breast disorders and in a certain percentage of apparently healthy individuals. The CA 15-3 elevations seen in non-cancerous conditions tend to be stable over time.
Laboratories may use different methods to test for CA 15-3, so results can vary from lab to lab. If you are having a series of CA 15-3 tests done, it is advised that you have the tests done by the same method, typically by the same laboratory, so that the results can be compared and interpreted correctly. You may wish to discuss this issue with your healthcare practitioner.
Levels of CA 15-3 are not usually measured immediately after breast cancer treatment begins. There have been instances of transient increases and decreases in CA 15-3 that do not correlate with the person's progress. Usually, the healthcare practitioner will wait a few weeks after starting treatment to begin monitoring CA 15-3 levels.
No. Although it has a different name, the CA 27.29 test measures the same protein as CA 15-3 and is used in the same way. It can be used instead of CA 15-3, but you don't need both tests.
CA 15-3 is not recommended as a screening tool. It is not specific or sensitive enough to detect early breast cancer. Elevations in CA 15-3 may be due to other causes, and a normal value does not ensure that you do not have cancer. As a rule, it should only be used after breast cancer has been diagnosed.
This depends on the laboratory performing the testing. Not every lab performs this test and your sample may need to be sent to a reference laboratory for testing. It may take several days to a week for results to be available.
Sources Used in Current Review
Pagana, Kathleen D., Pagana, Timothy J., and Pagana, Theresa N. (© 2015). Mosby's Diagnostic and Laboratory Test Reference. 12th Edition: Mosby, Inc., Saint Louis, MO. Pp 196.
Penn Medicine Oncolink® (28 April 2016 updated). Patient Guide to Tumor Markers. Available online at http://www.oncolink.org/treatment/article.cfm?id=296. Accessed February 2017.
National Cancer Institute (4 November 2015 reviewed). Tumor Markers. Available online at http://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet. Accessed February 2017.
Thaker NG (5 September 2014 updated). CA 15-3. Medscape Reference. Available online at http://emedicine.medscape.com/article/2087491-overview. Accessed February 2017.
Graham LJ, Shupe MP, Schneble ED, et al. Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer. Journal of Cancer. 2014; 5(1): 58-68. Published online 2014 Jan 5. doi: 10.7150/jca.7047
Molina R, Barak V, Duffy MJ, et al. Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. Available online at http://www.egtm.eu/professionals/breast_cancer. Accessed February 2017.
Chourin S, Georgescu D, Gray C, et al. Value of CA 15-3 Determination in the Initial Management of Breast Cancer Patients. Annals of Oncology. 2009:20(5):962-964. Published online 19 March 2009 doi:10.1093/annonc/mdp061.
Sources Used in Previous Reviews
Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].
Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.
Check, W. (1998 July) Reaching agreement on tumor markers. CAP Today, In the News [On-line journal]. Available online at http://www.cap.org/captoday/archive/1998/julycover.html.
NCI (1998 April 27). Tumor markers. National Cancer Institute, Cancer Facts [On-line information]. Available online at http://cis.nci.nih.gov/fact/5_18.htm.
ACS (2000 July 19). Tumor Markers. American Cancer Society, Prevention and Early Detection [On-line information]. Available online through http://www.cancer.org.
AACC (2001 July 27) Use of Tumor Markers in Cancer Patients Leads to Better Detection, Decreasing Mortality. AACC Media Center, American Association for Clinical Chemistry [On-line press release]. PDF available for download at http://www.aacc.org/media/TumorMarkers.pdf.
ASCO (1996 May 17, adopted, revision every 3 years). CA 15-3 as a Marker for Breast Cancer. American Society for Clinical Oncologists, Clinical Practice Guidelines for the Use of Tumor Markers in Breast and Colorectal Cancer [On-line guidelines]. Available online at http://www.asco.org/prof/pp/html/guide/tumor/m_tumor10.htm.
Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 214-215.
Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. Pp 247.
Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 206-207.
(Revised 2008 December 08). Tumor Markers. American Cancer Society [On-line information]. Available online at http://www.cancer.org/docroot/PED/content/PED_2_3X_Tumor_Markers.asp?sitearea=PED. Accessed August 2009.
(Updated 2009 May) Tumor Markers. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/resources/print/TumorMarkers.pdf. Accessed August 2009.
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER and Bruns DE, eds. 4th ed. St. Louis, Missouri: Elsevier Saunders; 2006, Pp 770-771.
Park, B et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Annals of Oncology 2008 19(4):675-681. Available online at http://annonc.oxfordjournals.org/cgi/content/full/19/4/675. Accessed September 2009.
Merck (2000). Cancer and the Immune System. The Merck Manual of Medical Information Home Edition, Section 15 Cancer, Ch 163 [On-line information]. Available online at http://www.merck.com/pubs/mmanual_home/sec15/163.htm.
Duffy, M. (1999). CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem [On-line journal]. Vol 36: 579-586. PDF available for download at http://www.leeds.ac.uk/acb/annals/annals_pdf/Sept%2099/ACB579.PDF.
Srirangam, S. and Harland, R. (2001). Management of Advanced Breast Cancer. Forum for Registrars In Surgical Training [On-line information]. PDF available for download at http://www.frist.org/asit/meetings/yearbook2001/BREAST%20CANCER.pdf.
(Revised 2012 October 18). Tumor Markers. American Cancer Society [On-line information]. PDF available for download at http://www.cancer.org/acs/groups/cid/documents/webcontent/003189-pdf.pdf. Accessed October 2012.
Thaker, N. et. al. (Updated 2012 May 24). CA 15-3. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/2087491-overview#showall. Accessed October 2012.
(© 1995-2012). Cancer Antigen 15-3 (CA 15-3), Serum. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/81607. Accessed October 2012.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 206-207.
Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 496, 500.
Pagana and Pagana. Mosby's Manual of Diagnostic and Laboratory Tests. Fourth Edition. Pg 142.